Monitoring of Bone Metabolism After Bone Marrow Transplantation by Measuring Two Different Markers of Bone Turnover

Clinical Chemistry and Laboratory Medicine

Volumn 34, Issue 3, 1996, Pages 193-198

  Withold, Wolfgang ^a   Kollbach, Sabine ^a,b   Reinauer, Hans ^a   Wolf, Hans Heinrich ^b   Heyll, Axel ^b   Schneider, Wolfgang ^b  

^a Institut für Klinische Chemie und Laboratoriumsdiagnostik   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; CYCLOSPORIN A; ESTROGEN; METHOTREXATE; PROCOLLAGEN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MASS; BONE METABOLISM; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ADULT; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE AND BONES; BONE MARROW TRANSPLANTATION; CROSS-SECTIONAL STUDIES; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN; SEX CHARACTERISTICS;

EID: 0030005047     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.1996.34.3.193     Document Type: Article

References (21)

1. Katz IA, Epstein S. Posttransplantation bone disease. J Bone Miner Res 1992; 7: 123-126.
2. Kelly PJ, Atkinson K, Ward RL, Sambrock PN, Biggs JC, Eisman JA. Reduced bone mineral density in men and women with allogeneic bone marrow transplantation. Transplantation 1990; 50: 881-883.
3. Van Straalen JP, Sanders E, Pummel MF, Sanders GTB. Bonealkaline phosphatase as indicator of bone formation. Clin Chim Acta 1991; 201: 27-34.
4. Melkko J, Niemi S, Risteli L, Risteli J, Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328-32.
5. Bergmeyer HU, Büttner H, Hillmann G, Kreutz FH, Lang H, Laue D, et al. Empfehlungen der Deutschen Gesellschaft für Klinische Chemie. Standardisierung von Methoden zur Bestimmung von Enzymaktivitäten in biologischen Flüssigkeiten. Experimentelle Begründung der optimierten Standard-Bedingungen. Z Klin Chem Klin Biochem 1972; 10: 182-192.
6. Szasz G. -Glutamyl-Transpeptidase. In: Bergmeyer HU, editor. Methoden der enzymatischen Analyse. Weinheim: Verlag Chemie, 1974: 757-762.
7. Sachs L. Statistische Methoden. Planung und Auswertung. 6th ed. Berlin, Heidelberg, New York, London, Paris, Tokyo: Springer, 1988.
8. Benker G, Schäfer U, Hermanns U, Mahmoud MK, Olbricht T, Schulte HM, et al. Allogeneic bone marrow transplantation in adults: endocrine sequelae after 1-6 years. Acta Endocrinol (Copenh) 1989; 120: 37-42.
9. Joffe I, Katz I, Jacobs T, Stein B, Takizawa M, Liu C, Berlin J, Epstein S. 17 β-estradiol prevents osteopenia in the oophorectomized rat treated with cyclosporin A. Endocrinology 1992; 130: 1578-86.
10. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123: 2571-7.
11. Stein B, Takizawa M, Schlosberg M, Movsowitz C, Fallon M, Berlin JA, Epstein S. Evidence that cyclosporine G is less deleterious to rat bone in vivo than cyclosporin A. Transplantation 1992; 53: 628-632.
12. Withold W, Degenhardt S, Castelli D, Heins M, Grabensee B. Monitoring of osteoblast activity with an immunoradiometric assay for determination of bone alkaline phosphatase mass concentration in patients receiving renal transplants. Clin Chim Acta 1994; 225: 137-146.
13. Loertscher R, Thiel G, Harder F, Brunner FP. Persistent elevation of alkaline phosphatase in cyclosporine-treated renal transplant recipients. Transplantation 1983; 35: 115-116.
14. Schmidt H, Stracke H, Schatz H, Scheuermann EH, Fassbinder W, Schoeppe W. Osteocalcin serum levels in patients following renal transplantation. Klin Wochenschr 1989; 67: 297-303.
15. Carlson K, Simonsson B, Ljunghall S. Acute effects of highdose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism. Calcif Tissue Int 1994; 55: 408-411.
16. Arnold JC, Hauser D, Ziegler R, Kommerell B, Otto G, Theilmann L, Wüster C. Bone disease after liver transplantation. Transplant Proc 1992; 24: 2709-10.
17. Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14: 296-300.
18. Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Amer J Med 1993; 94: 257-264.
19. Eriksen EF, Charles P, Melson F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone morphometry. J Bone Min Res 1993; 8: 127-132.
20. Francini G, Gonnelli S, Petrioli R, Bruni S, Marsili S, Aquino A, Camporeale A. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic activity. Cancer Epidemiol Biomarkers Prev 1993; 2: 125-129.
21. Smedsrod B, Melkko J, Risteli L, Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990; 271: 345-350.